APTEEUS

APTEEUS is part of this nice meeting in a nice place to face the challenges of drug repurposing! Request Adrien Paquot

𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗮𝘆 On Rare Disease Day 2024, we proudly stand with the rare disease community, recognizing the unique challenges faced by individuals and families. Today, let's join hands in raising awareness, advocating for improved resources, and supporting research that can bring new possibilities to patients. We extend our wholehearted support to organizations dedicated to patient advocacy, research funding, and community outreach. Alongside these organizations, we tirelessly promote collaboration among healthcare professionals, researchers, and policymakers, through +30 research programmes since 2013 : Lueur d'espoir pour Ayden , Les petits mecp2, La marche de Noé, ASAP for Children, Vaincre les maladies Lysosomales , Ma fumarase mon énergie, Le combat de Celya. As we honor this day, let's reaffirm our dedication to making a positive impact and addressing the unmet needs of patients by offering a therapeutic solution to each and every one of us. #RareDiseaseDay #ShowYourRare #ShareYourColours #LightUpForRare

𝗥𝗮𝗿𝗲 𝗟𝗶𝘃𝗲𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗻𝘁𝗵 February marks Rare Liver Disease Awareness Month, an important time to shine a light on the challenges faced by individuals battling uncommon liver conditions. Let's unite in raising awareness for rare liver diseases, acknowledging the shared journey of those facing liver dysfunction in its various forms, such as encountered by ZSD patients.  Together, we can make a difference in the lives of those affected by rare liver diseases and related conditions. #RareLiverDisease #RareLiverDiseaseMonth

APTEEUS sera présent à la prochaine web-conférence organisée par Pharmaceutiques le Jeudi 8 février 2024, qui aura pour thème « Maladies rares : un traitement pour tous ? ». Cet événement rassemblera des experts, chercheurs et professionnels de la santé pour partager et discuter des défis actuels. Terence Beghyn, président et co-fondateur d’APTEEUS, participera à la table ronde en exposant la stratégie ainsi que les actions menées à APTEEUS afin de répondre à certaines de ces problématiques. L’inscription à l’événement se fait via le lien suivant : https://lnkd.in/eNRTxKNQ

APTEEUS sera présent à la prochaine web-conférence organisée par Pharmaceutiques le Jeudi 8 février 2024, qui aura pour thème « Maladies rares : un traitement pour tous ? ». Cet événement rassemblera des experts, chercheurs et professionnels de la santé pour partager et discuter des défis actuels. Terence Beghyn, président et co-fondateur d’APTEEUS, participera à la table ronde en exposant la stratégie ainsi que les actions menées à APTEEUS afin de répondre à certaines de ces problématiques. L’inscription à l’événement se fait via le lien suivant : https://lnkd.in/eNRTxKNQ

APTEEUS develops drug research programmes. Its expertise is based on access to biological samples from patients, our know-how in the development of in vitro disease models and our 10 years of experience consolidated by numerous projects. We deliver results defining opportunities for drug repurposing or justifying compassionate uses. We operate in an ecosystem bringing together patients and their organizations, doctors and researchers. Tomorrow, we will bring new therapeutics for all of us, each of us.

APTEEUS develops drug research programmes. Its expertise is based on access to biological samples from patients, our know-how in the development of in vitro disease models and our 10 years of experience consolidated by numerous projects. We deliver results defining opportunities for drug repurposing or justifying compassionate uses. We operate in an ecosystem bringing together patients and their organizations, doctors and researchers. Tomorrow, we will bring new therapeutics for all of us, each of us.

Le développement de modèles expérimentaux, une des étapes décisives de la R&D médicaments. Un modèle doit être le reflet de ce qui se passe chez le patient, à l’échelle organique, cellulaire ou moléculaire. Il doit ainsi reproduire le phénomène biologique qui amène aux symptômes. Mais il doit également et surtout permettre la mise en évidence de mécanismes d’action correcteurs des déficits à l’œuvre chez le patient ! Enfin, il doit permettre d’évaluer un certains nombres de solutions thérapeutiques en un temps maîtrisé. Chez APTEEUS nous développons des modèles in vitro de maladies génétiques rares qui reproduisent parfaitement les mécanismes patho-physiologiques du patient et nous testons toutes les molécules repositionnables 💊

𝗔𝗣𝗧𝗘𝗘𝗨𝗦 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲𝘀 𝗶𝘁𝘀 𝟭𝟬𝘁𝗵 𝗮𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 ! It is with great pleasure that we share our 10th anniversary with you. A decade of research, discoveries and progress for our health. Years of commitment from our team, our associates, our partners and collaborators, and the patients themselves. We express our deep gratitude to all of you who contribute to the success of our projects. We continue to write the history of APTEEUS with our first program to develop a new drug, the arrival of new collaborators, new associates. Our projects will make APTEEUS the company reconciling the time of research with that of medicine, the rare with the common, the feasible with the achieved. We remain committed to our mission: addressing the unmet needs of patients by offering a therapeutic solution to each and every one of us.

𝗔𝗣𝗧𝗘𝗘𝗨𝗦 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲𝘀 𝗶𝘁𝘀 𝟭𝟬𝘁𝗵 𝗮𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 ! It is with great pleasure that we share our 10th anniversary with you. A decade of research, discoveries and progress for our health. Years of commitment from our team, our associates, our partners and collaborators, and the patients themselves. We express our deep gratitude to all of you who contribute to the success of our projects. We continue to write the history of APTEEUS with our first program to develop a new drug, the arrival of new collaborators, new associates. Our projects will make APTEEUS the company reconciling the time of research with that of medicine, the rare with the common, the feasible with the achieved. We remain committed to our mission: addressing the unmet needs of patients by offering a therapeutic solution to each and every one of us.